MBRX 8-K: SEC filing
Moleculin Biotech
Filed with the SEC on · accession 0001437749-26-037478
MBRX filed a 8-K (current report) with the SEC on Nov 18, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Summary of the filing
Moleculin Biotech announced that South Korea's Ministry of Intellectual Property issued a decision to grant a patent covering the company's method of reconstituting liposomal Annamycin (naxtarubicin), adding another major market to its international IP estate.
Key details
✦ Ask GOAX AI about this filing — what it means for MBRX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for MBRX?
Click hereFrequently asked questions
What did MBRX file with the SEC on Nov 18, 2026?
MBRX filed a 8-K (SEC filing). Moleculin Biotech announced that South Korea's Ministry of Intellectual Property issued a decision to grant a patent covering the company's method of reconstituting liposomal Annamycin (naxtarubicin), adding another major market to its international IP estate.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other MBRX SEC filings
Get alerts when MBRX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days